Was the Spyre Therapeutics (SYRE) CEO’s share sale made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. Such pre-arranged plans allow insiders to sell shares according to preset instructions.

Spyre Therapeutics (SYRE) CEO executes 15,000-share Rule 10b5-1 sale

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock in multiple open-market transactions on May 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan.

The sales occurred at weighted-average prices, with transaction price ranges disclosed between $69.25 and $74.96 per share across several blocks. After these transactions, the filing shows that Turtle continues to hold Spyre common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares ($1,070,507)

Net Sell 6 txns

Insider Turtle Cameron

Role Chief Executive Officer

Sold 15,000 shs ($1.07M)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,300	$69.54	$369K
Sale	Common Stock	3,600	$70.77	$255K
Sale	Common Stock	1,000	$71.76	$72K
Sale	Common Stock	3,100	$73.14	$227K
Sale	Common Stock	1,700	$74.23	$126K
Sale	Common Stock	300	$74.96	$22K

Holdings After Transaction: Common Stock — 622,240 shares (Direct, null)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $71.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.41 to $72.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.75 to $73.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.95 to $74.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.95 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 15,000 shares Sale price example 1: $74.96 per share Sale price example 2: $69.54 per share +3 more

6 metrics

Shares sold 15,000 shares Total common stock sold on May 1, 2026

Sale price example 1 $74.96 per share Weighted-average price for 300-share block

Sale price example 2 $69.54 per share Weighted-average price for 5,300-share block

Trade range low $69.25 Lowest price in disclosed sale ranges

Trade range high $74.96 Highest price in disclosed sale ranges

Transactions classified as sales 6 transactions Open-market common stock sales on May 1, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, common stock, vesting

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

common stock financial

"Includes 101,653 shares of common stock that vest in monthly installments"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"shares of common stock that vest in monthly installments through November 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 09:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		S⁽¹⁾		5,300	D	$69.54⁽²⁾	622,240⁽³⁾	D
Common Stock	05/01/2026		S⁽¹⁾		3,600	D	$70.77⁽⁴⁾	618,640⁽³⁾	D
Common Stock	05/01/2026		S⁽¹⁾		1,000	D	$71.76⁽⁵⁾	617,640⁽³⁾	D
Common Stock	05/01/2026		S⁽¹⁾		3,100	D	$73.14⁽⁶⁾	614,540⁽³⁾	D
Common Stock	05/01/2026		S⁽¹⁾		1,700	D	$74.23⁽⁷⁾	612,840⁽³⁾	D
Common Stock	05/01/2026		S⁽¹⁾		300	D	$74.96⁽⁸⁾	612,540⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $71.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.41 to $72.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.75 to $73.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.95 to $74.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

8. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.95 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Spyre Therapeutics (SYRE) report on this Form 4?

Spyre Therapeutics reported that CEO Cameron Turtle sold 15,000 shares of common stock. The transactions were open-market sales executed in multiple blocks on May 1, 2026, as disclosed in the Form 4 filing.

At what prices did Spyre Therapeutics (SYRE) CEO Cameron Turtle sell shares?

Cameron Turtle’s sales used weighted-average prices with ranges between $69.25 and $74.96 per share. Each sale block had its own price range, reflecting numerous individual trades within those disclosed intervals.

How many Spyre Therapeutics (SYRE) shares did the CEO sell in total?

The Form 4 shows that CEO Cameron Turtle sold a total of 15,000 shares of Spyre Therapeutics common stock. This total reflects six separate open-market sale transactions reported for May 1, 2026.

What type of security did the Spyre Therapeutics (SYRE) Form 4 transactions involve?

All reported transactions involved Spyre Therapeutics common stock as non-derivative securities. No options or other derivatives were exercised or converted in this filing, and the derivative position summary is empty.

Does the Spyre Therapeutics (SYRE) CEO still hold shares after these sales?

Yes. The Form 4 includes share balances reported as "shares following transaction" for each sale entry, indicating that Cameron Turtle continues to hold Spyre Therapeutics common stock directly after the reported trades.